Ajuts a la recerca

EFSD/MSD European Research Programme on Novel Therapies for Type 2 Diabetes

Organisme

EFSD and MSD have established a European Research Programme for preclinical and translational research on Novel Therapies for Type 2 Diabetes to encourage new projects aimed at identifying novel new targets for the treatment of type 2 diabetes.

Objecte

Background

The European Foundation for the Study of Diabetes (EFSD) was created by the European Association for the Study of Diabetes (EASD) to provide funding initiatives in all areas of diabetes research. The aims of EFSD are to encourage and support research in the field of diabetes, to rapidly diffuse acquired knowledge and to facilitate its application.

Merck & Co., Inc is a global, research-driven pharmaceutical company. Merck discovers, develops, manufactures and markets a broad range of innovative products to improve human and animal health, directly and through its joint ventures. Merck Sharpe & Dohme, or MSD, is the name Merck uses for conducting its business in all other countries outside the United States and Canada.

Programme and Research Focus

EFSD and MSD have established a European Research Programme for preclinical/translational research on novel therapies to encourage the identification of new targets for the treatment of type 2 diabetes.

To achieve the goals and objectives of this Programme, EFSD and MSDinvite applications by issuing this "Request for Applications" (RFA), which indicates joint funding as well as areas of research emphasis.

The EFSD/MSD European Research Programme on Novel Therapies for Type 2 Diabetes is intended to stimulate and accelerate European research focusing on the identification and molecular understanding of new targets for the treatment of type 2 diabetes.

Proposals may include but are not limited to:
Mechanisms to induce “browning of adipose tissue”
Novel targets for improving skeletal muscle or adipose tissue insulin resistance
Bile acid biology as it relates to metabolic disease. This includes actions relating to glucose metabolism, lipid metabolism, energy balance and related diseases including diabetes, atherosclerosis and obesity
Lipid metabolism as it relates to insulin action
Mechanisms of glucose-dependent insulin and glucagon secretion

Mechanism of Support and Review

Research will be supported through the award of grants, each of up to Euro 100,000, payable in the first year and in one instalment. The duration of each award may be one year or longer, depending upon the needs of the project and as justified in the application. EFSD may, on advisement from the Review Committee, recommend an award in a different amount from that requested, but which is considered more appropriate for the proposed studies.

Applications for an EFSD/MSDgrant are invited from single non-profit institutions or groups of such institutions from Europe and associated countries. The principal investigator and any co-investigators must be employed full-time at a non-profit institution and the study must be performed at their place of work.

Applications will be subject to scientific review by a specialised and independent ad hoc committee. It is anticipated that applications will be received, reviewed and approved for funding by June 2014.

Prior to any final decision on funding, and in order to offer applicants the opportunity to benefit from the review process, EFSD reserves the right to request revision to applications in accordance with the recommendations of the Review Committee.